Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
AmericanUveitisSocietySpringMeeting2015 chairedby TammyM.Martin,PhDCaseyEyeInstitute,OHSU&DeversEyeInstitute,LRI Rooms708/710/712,ColoradoConventionCenter 2May,2015 Program 5.00PM SocialHour(Room703) 6.00PM PlenarySession:BasisforandUsesofBiologicDrugsinUveitis RachelCaspi,PhD NationalEyeInstitute,NationalInstitutesofHealth “MirroringtheClinicalandImmunologicalComplexityofAutoimmuneUveitisin AnimalModels” EricB.Suhler,MD,MPH OregonHealth&ScienceUniversity,VAPortlandHealthCareSystem “BiologicWarfareonUveitis:PerspectivesfromtheClinic” 7.00PM BusinessMeeting 7.30PM Freepapers 7.30PM GaryHolland,MD:InteractionbetweenKillerImmunoglobulin-like Receptor(KIR)Gene-HLACombinationsandParasiteSerotypesamong HispanicIndividualsatRiskforOcularToxoplasmosis 7.45PM DouglasA.Jabs,MD,MBA:Long-termOutcomesofCytomegalovirus RetinitisintheUnitedStatesintheEraofModernAntiretroviral Therapy 8.00PM JohnA.Gonzales,MD:QualityofLifeOutcomesfromaRandomized ClinicalTrialforNoninfectiousIntermediate,Posterior,andPan- Uveitis 1 8.15PM 8.30PM 8.45PM 9.00PM 9.15PM 9.30PM AliK.Tayyeba,MD:ManagementofEndStageCornealDiseaseand ChronicUveiticHypotonybyCombiningtheBostonType1 KeratoprosthesiswithParsPlanaVitrectomyandSiliconeOilFill DanielLFeiler,MD:TreatmentofUveiticCystoidMacularEdema withTopicalDifluprednate. LauraJ.Kopplin,MD:Peginterferonalfa-2a(PEGASYS)inthe TreatmentofInflammatoryCystoidMacularEdema BlakeA.Isernhagen,MD:AutoimmuneRetinopathy:AGuidefor CliniciansBasedonRecommendationsofanExpertPanel SarjuS.Patel,MD:TheUtilityandLimitationsofWide-Field AutofluorescenceinInflammatoryChoroiditis FriederikeMackensen,MD:IsThereaCorrelationBetweenMultiple SclerosisandFuchsUveitis 2 ABSTRACTS InteractionbetweenKillerImmunoglobulin-likeReceptor(KIR)Gene-HLACombinations andParasiteSerotypesamongHispanicIndividualsatRiskforOcularToxoplasmosis Authors GaryN.Holland,1ADavidC.Reed,1AChristianJ.Sanfilippo,1AFeiYu,1AJeffreyL.Jones,2PatrickA. Coady,3LeanneT.Labriola,4Ann-MarieLobo,5YingQian,6JoseG.Montoya,7MichaelE.Grigg,8Raja Rajalingam,1BandtheNorthAmericanOcularToxoplasmosisStudyGroup. AuthorAffiliations A OcularInflammatoryDiseaseCenter,SteinEyeInstituteandDepartmentofOphthalmology. B ImmunogeneticsLaboratory,DepartmentofPathologyandLaboratoryMedicine. 1 DavidGeffenSchoolofMedicineatUCLA,LosAngeles,CA. 2 ParasiticDiseaseBranch,DivisionofParasiticDiseasesandMalaria,CenterforGlobalHealth, CentersforDiseaseControlandPrevention,Atlanta,GA. 3 DartmouthMedicalSchool,Lebanon,NH. 4 DepartmentofOphthalmology,UniversityofSouthernCalifornia,LosAngeles,CA. 5 MassachusettsEyeandEarInfirmary,HarvardMedicalSchool,Boston,MA. 6 FrancisI.ProctorFoundationandDepartmentofOphthalmology,UCSanFrancisco,San Francisco,CA. 7 DepartmentofImmunologyandInfectiousDiseases,StanfordUniversitySchoolofMedicine, Stanford,CA. 8 MolecularParasitologyUnit,LaboratoryofParasiticDiseases,NIAID,NIH,Bethesda,MD. Abstract Purpose:Toinvestigaterelationshipsbetweenoculartoxoplasmosisandthefollowingfactors amongT.gondii-infectedHispanics:killerimmunoglobulin-likereceptor(KIR)genes;HLAtypes; KIR/HLAcombinations;andparasiteserotypes.WealsosoughtevidenceofKIR/HLAcombinationserotypeinteractions. Methods:Weevaluated88T.gondii-infectedHispanicadultswhodid(n=37)ordidnot(n=51) havetoxoplasmicretinochoroiditis.SerotypesweredeterminedwithanELISAthatidentifiedhost antibodiesagainst8peptidesassociatedwithgenotype-specificalleles.Oddsratios(ORs)forocular involvementamongthosewithnon-TypeIIinfectionsvs.thosewithTypeIIinfectionswere calculatedforsubgroupswithandwithoutvariousKIR/HLAcombinations.TheBreslow-Daytest forhomogeneityofORsbetween2groupswasusedtoidentifyinteractionsbetweenKIR/HLA combinationsandserotype. Results:OcularinvolvementwasnotsignificantlyassociatedwithserotypeoranyKIRgenein crudeanalyses.Ocularinvolvementwasassociatedwiththefollowingfactors:HLAtypesA68 (p=0.0002),B39(p=0.011),B65(p=0.038),andC06(p=0.011);HLAGroupC1(p=0.0006);and KIR/HLAcombinationKIR2DL2/2DL3/HLA-C1(p=0.0006).Thereappearedtobeinteractions betweenserotypeandatleast6of10KIR/HLAcombinationschosenprospectivelyfortesting. Regardingriskofocularinvolvementwithnon-TypeIIinfections,eachof4KIR/HLAcombinations wasassociatedwithincreasedriskofocularinvolvement,whileabsenceofeachofthesame combinationswasassociatedwithdecreasedrisk.Thereversewasobservedfor2KIR/HLA combinations. 3 Conclusion:HostfactorscaninfluenceriskofocularinvolvementamongT.gondii-infected individuals,evenwithoutevidenceofimmunedysfunction.Parasitevirulencelikelydependson interactionsofhostandparasite-derivedgeneproducts,asdemonstratedinanimalmodels.Study oftheseinteractionsmayprovideinsightintooculardiseasepathogenesis. ThisresearchisNOTaclinicaltrial. Disclosure(s) None Support ResearchtoPreventBlindness,Inc,NewYork,NY(Dr.Holland);CentersforDiseaseControland Prevention,Atlanta,GA(Drs.Holland,Jones);theSkirballFoundation,NewYork,NY(Dr.Holland), theAltaCaliforniaEyeResearchFoundation,SanFrancisco,CA(Dr.Sanfilippo),andtheIntramural ResearchProgramoftheNationalInstitutesofHealth,NIAID(Dr.Grigg).Dr.GriggisaScholarofthe CanadianInstituteforAdvancedResearch(CIFAR)IntegratedMicrobialBiodiversityProgram. 4 Long-termOutcomesofCytomegalovirusRetinitisintheUnitedStatesintheEraofModern AntiretroviralTherapy Authors Jabs,Douglas;AhujaAlka;VanNatta,Mark;Lyon,Alice;Yeh,Steven;Danis,Ron AuthorAffiliations FromtheDepartmentsofOphthalmologyandMedicine,theIcahnSchoolofMedicineatMount Sinai;theCenterforClinicalTrials,theDepartmentofEpidemiology,TheJohnsHopkinsUniversity BloombergSchoolofPublicHealth;theDepartmentofOphthalmology,theNorthwesternUniversity FeinbergSchoolofMedicine;theDepartmentofOphthalmology,theEmoryUniversitySchoolof Medicine;andtheDepartmentofOphthalmology,theUniversityofWisconsin,Madison. Abstract PURPOSE:Todescribethelong-termoutcomesofpatientswithcytomegalovirus(CMV)retinitis andtheacquiredimmunodeficiencysyndrome(AIDS)intheeraofmoderncombination antiretroviraltherapy(ART). METHODS:Prospective,observational,UnitedStatescohortof479patientswithAIDSandCMV retinitisdiagnosedintheeraofmodernART.Patientswerecategorizedasimmunerecovered, definedasaCD4+Tcellcount>100cells/µLfor>3months,ornot.Outcomesincludedmortality, visualimpairment(visualacuityworsethan20/40),blindness(visualacuity20/200orworse),and lossofvisualfieldonquantitativeGoldmannperimetry. RESULTS:Patientswithoutimmunerecoveryhadamortalityof44.4/100person-years(PY),anda mediansurvivalof13.5monthsafterthediagnosisofCMVretinitis,whereasthosewithimmune recoveryhadamortalityof2.7/100PY,andanestimatedmediansurvivalof27.0years.Therates ofbilateralvisualimpairmentandblindnesswere0.9/100PYand0.4/100PY,respectively,anddid notdifferbyimmunerecoverystatus.Ratesofvisualfieldlosswere7%ofthenormalfield/year forthosewithoutimmunerecoveryand1%/yearforthosewithimmunerecovery. CONCLUSIONS:AmongpersonswithAIDSandCMVretinitis,long-termsurvivalispossible,ifthere isimmunerecovery.Ifthereisnoimmunerecovery,themortalityrateissubstantialandsimilarto thepre-modernARTera.Althoughlow,theratesofbilateralvisualimpairmentandblindnessare greaterthanthoseseeninanHIV-uninfectedpopulation. ThisresearchisNOTaclinicaltrial. Disclosure(s) None Support NEIcooperativeagreementsU10EY08052,U10EY08057,U10EY08067. 5 QualityofLifeOutcomesfromaRandomizedClinicalTrialforNoninfectiousIntermediate, Posterior,andPan-Uveitis Authors Gonzales,JohnA.,MD1,5Rathinam,SivakumarR.,MD,PhD2,Babu,Manohar,MD3,Thundikandy, Radhika,MD2,Kanakath,Anuradha,MD3,Browne,EricaN.,MS1,Acharya,NishaR.,MD,MS1,4,5 AuthorAffiliations Institutions:1F.I.ProctorFoundation,UniversityofCalifornia,SanFrancisco;2AravindEyeCare System,Madurai,India;3AravindEyeCareSystem,Coimbatore,India;4Departmentof Epidemiology&Biostatistics,UniversityofCalifornia,SanFrancisco;5Departmentof Ophthalmology,UniversityofCalifornia,SanFrancisco Abstract Purpose:Toevaluatequalityoflife(QOL)changesinpatientstreatedwithmethotrexate(MTX)or mycophenolatemofetil(MMF)fornon-infectiousintermediate,posterior,orpan-uveitis. Methods:Thisisasecondaryanalysisfromaclinicaltrialof80patientsenrolledinarandomized observer-maskedtrialtocomparetheeffectivenessofMTXvs.MMF.Patientsreceivedsystemic corticosteroidswhichweretaperedaccordingtoSUNguidelines.PatientswereenrolledatAravind EyeHospitalinIndiaandfollowedmonthlyfor6months.Themainoutcomewastheproportionof patientsachievingcorticosteroid-sparingcontrolofinflammation.QOLmeasurementswere collectedatbaselineandatthefinalstudyvisitusingtheIndianVisionFunctionQuestionnaire (IND-VFQ33)andtheShortFormHealthSurvey(SF-36).T-testswereusedtocomparechangesin scoresandFishersexacttestwasusedtocompareproportions. Results:67patientswithcompletefollow-upwereincludedintheanalysis.Overall,theIND-VFQ33 compositescoreimprovedbyanaverageof9.7points(95%confidenceinterval(CI):5.6,13.9, p<0.001).Therewasnostatisticallysignificantdifferenceinimprovementbytreatmentgroup (p=0.86).TheVFQcompositescoreimprovedfor97%oftreatmentsuccessescomparedto68%of treatmentfailures(p=0.001).Ingeneral,therewasnosignificantchangeintheSF-36physical componentsummaryscore(p=0.58),buttherewasaslightdecreaseinthementalcomponent summaryscore(meanchange-1.8points,95%CI:-3.8,0.1p=0.07).Thiswasmainlyduetoa decreaseinthevitalitydomain(meanchange-3.2points,95%CI:-5.3,-1.2,p=0.002). Conclusions:Vision-relatedQOLimprovedwithimmunosuppressanttreatment.Therewas consistentimprovementinthosewhowereatreatmentsuccessandresultsweremixedfor treatmentfailures.Therewasnochangeinthephysicalcomponentofgeneralhealth,buttherewas asignificantdecreaseinvitalityinbothtreatmentgroups. ThisresearchISaclinicaltrialandisregisteredatwww.clinicaltrials.gov. Disclosure(s) None Support FundingforthistrialwasprovidedbyThatManMaySeeandTheSouthAsiaResearchFund. 6 ManagementofEndStageCornealDiseaseandChronicUveiticHypotonybyCombiningthe BostonType1KeratoprosthesiswithParsPlanaVitrectomyandSiliconeOilFill Authors TayyebaK.Ali,MD,1GuillermoAmescua,MD,1AllisterGibbons,MD,1VictorL.Perez,MD1,JanetL. Davis,MD,1 AuthorAffiliations 1DepartmentofOphthalmology,BascomPalmerEyeInstitute,UniversityofMiamiMillerSchoolof Medicine;Miami,FL. Abstract PURPOSE: ToreviewtheoutcomesofBostontype1keratoprosthesis(B-KPro)implantationincombination withparsplanavitrectomyandsiliconeoilforthetreatmentofendstagebullouskeratopathyand uveitichypotony. METHODS: Thiswasaretrospectivechartreview.Sixeyesof5patientsunderwentB-KProimplantation,pars planavitrectomy,andsiliconeoilplacement.Allpreoperativecharacteristics,includingvisual acuityandintraocularpressure,intraoperativeevents,andpostoperativeoutcomeswereanalyzed. RESULTS: Meanpatientagewas63.9years(range40.9-86.4years).Meanpre-operativeBCVAwaslogMAR 2.73(range2.60to3.00).Initially,againofvisualacuitywasseeninhalfthesamplewithmean BCVAlogMAR1.90(Range0.90to3.00).Atfinalfollow-up(mean25.8monthsandrange12to52 months),meanvisualacuitywaslogMAR2.23(range1.20to3.00)andnoeyelostvision.Twoeyes (33%)hadpreviouslyundergonecornealtransplantation,oneofwhichwasanendothelial keratoplasty(DSAEK).Theother4eyeshadaB-Kproastheirfirstcornealprocedure.No intraoperativecomplicationsoccurred,thoughonepatienthadaconcomitantretinaldetachment (RD)repairforpre-existingRD.B-KProretentionratewasonehundredpercent.Onepatient developedaretroprostheticmembrane(RPM);nopatientsexperiencedcomplicationssuchasmelt, endophthalmitis,orextrusion.TheonepatientwhohadanRPMhadapsuedophakicB-Kpro,which mayhavecontributedtopersistenceofRPM.Therewerenouveiticflaresandhypotonywas controlled,thoughfurtherintervention,includingrepeatSOfillinonepatient,wasrequiredover theextendedfollow-upofthesepatients. CONCLUSIONS: B-KProimplantationincombinationwithparsplanavitrectomyandintraocularsiliconeoilfillisa safe,thoughend-stage,procedurethatmaintainscontrolofuveitis,canimprovevisioninsome chronicallyhypotonouseyes,andmaydelayorpreventphthisis. ThisresearchisNOTaclinicaltrial. Disclosure(s) None Support None 7 TreatmentofUveiticCystoidMacularEdemawithTopicalDifluprednate. Authors Feiler,DanielL;Srivastava,SunilK;Lowder,CareenY AuthorAffiliations ClevelandClinic,ColeEyeInstitute Abstract Purpose:Cystoidmacularedema(CME)isacommoncauseofvisionlossinpatientswithuveitis. Evidenceforoptimaltreatmentstrategiesislacking.Thepotency,limitedsystemicabsorption,and non-invasivenatureoftopicaldifluprednatemakeitanattractivetreatmentoptionwhencompared totraditionalornoveltreatments.Weretrospectivelyreviewedtheefficacyofdifluprednate ophthalmicemulsion0.05%inthetreatmentofCMEinpatientswithuveitis. Methods:Twentytwoeyesof18patientswithuveiticCMEtreatedwithtopicaldifluprednatefour timesdailyfor3weeksandtaperedover1monthwerereviewedforbest-correctedSnellenvisual acuity(VA),centralfovealthickness(CFT)onopticalcoherencetomography(OCT),andintraocular pressure(IOP).Amixedmodelwasfitwitheachmeasureastheoutcome,andvisittimeasthe primarypredictor,withpatientandeyeasrandomeffects.AnalyseswereperformedusingSAS software(version9.3;Cary,NC).Asignificancelevelof0.05wasassumedforalltests. Results:Twentytwo(100%)eyeshadadecreaseinCFTatfollow-up.MeanCFTdecreasedby 121μm(P<0.001)at30days±15days(21eyes),and137um(p<0.001)at60days±15days(12 eyes).Sixof21(28%)eyeshadcompleteresolutionofIRFat30days±15days,while8of12(66%) hadcompleteresolutionofIRFat60days±15days.LogMARVAimprovedbyameanof0.160 (P=0.013)andVAimprovedbyatleast1linein9of12eyes(75%)(P=0.013)at60days±15days. MeanincreaseinIOPwas2.0mmHgat30days±15days(P=0.040)and2.2mmHgat60days±15 days(P=0.086).Nosignificantocularorsystemicadverseeffectswereobserved. Conclusions:Theseresultssuggestthattopicaldifluprednateisawell-toleratedandeffective treatmentforuveiticCMEwithdecreasedOCTCFT,mildimprovementinVA,andmildelevationof IOPinthestudiedpatients.FurtherevaluationoftopicaldifluprednateforuveiticCMEincontrolled randomizedstudiesiswarranted. ThisresearchisNOTaclinicaltrial. Disclosure(s) DanielFeiler(none),SunilSrivastava(Alcon,Allergan,BauschandLomb),CareenLowder(None) Support None 8 Peginterferonalfa-2a(PEGASYS)intheTreatmentofInflammatoryCystoidMacularEdema Authors Kopplin,LauraJ.[1];Stiefel,HillaryC.[1];Vegunta,Sravanthi[2];Albini,ThomasA.[2];Suhler,Eric B.[1,3] AuthorAffiliations [1]CaseyEyeInstitute,Portland,OR [2]BascomPalmerEyeInstitute,Miami,FL [3]VAPortlandHealthCareSystem,Portland,OR Abstract Purpose:Toassesstheutilityofpeginterferonalfa-2a(PEGASYS)inthetreatmentofrefractory inflammatorycystoidmacularedema(CME). Methods:Weconductedaretrospectivechartreviewoffourpatientswithrecalcitrant inflammatoryCMEtreatedwithpeginterferonalfa-2aatthePortlandVAHealthCareSystemand BascomPalmerEyeInstitute. Results:ThreepatientshadCMEsecondarytochronicbilateralidiopathicanteriorand intermediateuveitisandonepatienthadprimaryidiopathicCMEwithoutaknownhistoryof uveitis.Allpatientsfailedmultipletreatmentregimenswithlocaland/orsystemictherapiesprior toinitiationoftreatmentwithpeginterferonalfa-2a.Peginterferonalfa-2atherapyresultedin improvementincentralmacularthickness(CMT)inallpatients(averageCMTwas475μmpretreatment(range304-752),279μmpost-treatment(range204-373),Wilcoxonsigned-ranktest p<0.05)andresolutionofcysticintraretinalfluidinallcases.Visualacuityimprovedinthe majorityofpatients;onepatienthadsignificantpreexistingphotoreceptoratrophylimitingvisual recovery.Fatigueandflu-likesymptomsoccurredinthreepatientsandresultedintwopatients electingtodiscontinuetherapywithresultantrecurrenceofCME. Conclusions:Peginterferonalfa-2aisaneffecttreatmentforrefractoryinflammatoryCME,although sideeffectsmaylimitpatienttolerability. ThisresearchisNOTaclinicaltrial. Disclosure(s) Nonerelevanttothispresentation Support UnrestrictedinstitutionalgranttotheCaseyEyeInstitutefromResearchtoPreventBlindness, DepartmentofVeteransAffairs(Dr.Suhler). 9 AutoimmuneRetinopathy:AGuideforCliniciansBasedonRecommendationsofanExpert Panel Authors BlakeA.Isernhagen,MD1,HassanA.Aziz,MD1,LuciaSobrin,MD2,StevenK.Lundy,PhD3,JohnR. Heckenlively,MD3,DebraA.Goldstein,MD4,ThiranJayasundera,MD3,JanetL.Davis,MD1 AuthorAffiliations 1DepartmentofOphthalmology,BascomPalmerEyeInstitute,UniversityofMiami,MillerSchoolof Medicine,Miami,FL;2DepartmentofOphthalmology,MassachusettsEyeandEarInfirmary, HarvardMedicalSchool,Boston,MA;3DepartmentofOphthalmology,KelloggEyeCenter, UniversityofMichiganMedicalSchool,AnnArbor,MI;4DepartmentofOphthalmology, NorthwesternUniversityFeinbergSchoolofMedicine,Chicago,IL Abstract Purpose:Toprovideclinicianswithguidanceindiagnosingandinterpretingancillarytesting, proposingdifferentmodalitiesoftreatmentdependingonthediseaseseverity,andorganizingthe follow-upcareofpatientswithnon-paraneoplasticautoimmuneretinopathy(np-AIR). Methods:Physiciansandimmunologistswithexperienceinthediagnosisofnp-AIRconvenedatthe BascomPalmerEyeInstitute.Thepanelreviewedavailableliteratureandcasepresentationsof presumptivenp-AIRcollectedfromtertiaryuveitispractices.Afterroundtablediscussions,a writinggroupagreedtosummarizetheopinionsofthegroupregardingidentificationofcases, selectionofancillarytestsandevaluationofproposedtreatmentsbasedonthecurrentstateof knowledgeandthecurrentmanagementpracticesintertiarycaresubspecialtyclinics. Results:Recommendationsweremaderegardingtheutilityandinterpretationofthepatient’spast medicalhistoryandsymptoms,clinicalexamfindings,andancillarytestingtohelpdiagnosisand distinguishnp-AIRfromparaneoplasticretinopathyandretinaldegenerations.Ancillarytesting includeselectroretinography,fundusautofluorescence,opticalcoherencetomography,fluorescein angiography,evaluationforanti-retinalantibodies,andscreeningforsystemicmalignancy.In slowlyprogressivesuspectednp-AIRthetreatmentisusuallyimmunosuppression.Inrapidly progressivedisease,intravenouscorticosteroids,plasmapharesis,andintravenous immunoglobulinsaresometimesused.Thereisnoproventherapy.Thedisappearanceof antibodiesbywestern-blotafter6monthsoftreatmentsuggeststhatsufficienttreatmenthasbeen given,butdeterminingthebenefitsoftreatmentremainsdifficultbecausevisualfunctionrarely improves. Conclusions:Theobservationsandrecommendationsfromthepanelhelpcliniciansdiagnoseand treatpatientswithnp-AIR.Italsoservesasaplatformforfurtherresearchinthisfield. ThisresearchisNOTaclinicaltrial. Disclosure(s) NONE Support NONE 10 TheUtilityandLimitationsofWide-FieldAutofluorescenceinInflammatoryChoroiditis Authors Patel,SarjuS AuthorAffiliations WeillCornellMedicalCollege Abstract PURPOSE:Toreportontheusefulnessofwide-fieldfundusautofluorescence(FAF)intheclinical evaluationandmanagementofinflammatorychoroiditis METHODS:Retrospectivecase-series RESULTS:FAFimagingwasevaluatedin15casesofinflammatorychoroiditis,includingbothpan- andposterioruveitisentities.FindingsonFAFwerepresentin14of15cases.However,these findingswerenotfoundtobeusefulintheclinicalmanagementofthesepatientsbeyondfindings onotherimagingmodalities(opticalcoherencetomography,angiography,andcolorfundus photography)in10of15cases,whichincludedallpatientswithVKHsyndromeandbirdshot chorioretinopathy.FAFwashelpfulinpatientswithidiopathicchoroiditisandvariantsofacute zonaloccultouterretinopathy,withsubtlefindingscorrelatingwithvisualfielddefectsand subjectivevisualchanges,whichdictatedchangesinclinicalmanagement. CONCLUSIONS:WhileFAFfindingsarepresentinmostcasesofchoroiditis,FAFisclinicallyuseful inasubsetofpatientswherechangescancorrelatewithvisualfielddefectsandhelpdictatethe managementofthepatient. ThisresearchisNOTaclinicaltrial. Disclosure(s) None Support None 11 IsThereaCorrelationBetweenMultipleSclerosisandFuchsUveitis? Authors Mackensen,Friederike;Kansupada,Kashyap;Zamir,Ehud AuthorAffiliations InterdisciplinaryUveitisCenterUniversityofHeidelberg,Germany CharlotteEyeEarNose&ThroatAssociates,P.A.,USA RoyalVictorianEyeandEarHospitalMelbourne,Australia Abstract Purpose:MembersoftheAmericanUveitisSocietydiscussedtheirobservationthatpatientswith MultipleSclerosis(MS)maypresentwithFuchsUveitis(FUS)whichseemedtobemoreoften bilateral.FUSissupposedtobecausedbyrubellainfectionandinMSaviralpathogenesishasbeen discussedaswell.Acorrelationwashypothesized. Methods:Retrospectivedatabasereviewofonecenter.AllpatientswithFUS,allpatientswithMS andthosewithbothdiagnosesweresearchedforandevaluatedforanatomiclocalization,laterality andinthosepatientswithbothdiagnosesalsoforvisualaccuity,complicationsanddetailsof uveitispresentation.Additionalpatientswithbothdiagnosesfromothercenterswereadded. Results:Inthedatabase289patientswerelistedwithFUS,194withMSand4withbothdiagnoses. Thus,2%ofMSpatientshadFUSand1.4%ofFUSpatientshadMS.Additionally,5morepatients withbothdiagnoseswereadded,sowehadacaseseriesof9patientswithMSandFUS.Bilateral uveitiswasseenin11%ofFUSand33%ofFUS/MS.AllFUS/MShadstellatekeraticprecipitates and7cataract,6hadheterochromia,3of3testedhadrubellaantibodiesinaqueoushumorand2 hadsecondaryglaucomawith1requiringsurgery.Medianageatdiagnoseswas31and28forMS andFUS,respectively,and67%werefemale. Conclusion:MSoccurrsinaproximately0.2%ofthepopulation,FUSin0.05%.Thereforethe coincidenceofFUSandMSseemstobeslightlyhigherthantobeexpected.Ifthisisduetoahigher susceptibilitytorubellathroughMSorevenapathogeneticlinktorubellainMSremains speculative. ThisresearchisNOTaclinicaltrial. Disclosure(s) None Support None 12